Albert Bourla, Pfizer CEO (Hannes P Albert/picture-alliance/dpa/AP Images)
February 19, 2025 10:05 AM ESTUpdated 12:05 PM
Pharma

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Andrew Dunn

Senior Biopharma Correspondent

WASH­ING­TON — Over 500 phar­ma ex­ec­u­tives, lob­by­ists, con­sul­tants and oth­er in­dus­try mem­bers gath­ered a cou­ple miles from the White House on Tues­day, as top in­dus­try lead­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

In a blow to its obe­si­ty pipeline, Pfiz­er drops oral drug af­ter liv­er in­jury case

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times